D-Wave Stock Skyrockets 62% After Q1 Earnings: Time to Buy QBTS?

D-Wave Quantum's first-quarter release sparked a sharp rerating, with bookings up 1,994% year over year to a record $33.4 million, remaining performance obligations up 563% to $42.4 million, and the stock rising 61.6% since May 19. Management said most 2026 revenue will be recognized in the second half, supported by a $20 million university system sale, a $10 million QCaaS deal, and a more than doubled pipeline. The offset is still-high execution risk and an expensive valuation, with forward P/S at 179.3x and elevated operating losses after the Quantum Circuits acquisition.

Analysis

QBTS is being rewarded for a classic quantum-software-to-hardware inflection: bookings and RPO are now large enough to force investors to underwrite a more credible revenue bridge into 2H26, but the market is still pricing option value rather than durable cash generation. The second-order effect is that the company’s expanding backlog can support a higher multiple for longer, yet it also raises the bar on execution because any slip in delivery, acceptance, or customer provisioning will now be visible against a much larger expectation set.

The more interesting signal is competitive positioning. A dual-platform architecture improves narrative breadth, but it also increases capital intensity at exactly the moment when the sector is beginning to differentiate between research legitimacy and commercial throughput. That should pressure smaller peers with weaker liquidity or narrower product sets; if QBTS keeps converting enterprise QCaaS into recognized revenue, the financing gap versus gate-model rivals could widen over the next 2-3 quarters.

The contrarian risk is that the market is extrapolating bookings momentum into a smooth 2026 ramp when the real bottleneck is likely milestone timing. Large system deals can create lumpy revenue recognition and operating leverage in either direction, so the stock can keep ripping on headline pipeline updates while fundamentals remain noisy. With a forward sales multiple already embedding near-perfect execution, the setup is asymmetric only if management can prove recurring enterprise pull-through by year-end; otherwise the move looks more like a sentiment re-rate than a durable re-underwrite.

Key Decisions for Investors

• Stay tactically long QBTS only on pullbacks after sharp post-earnings extension; use a 6-12 week horizon and treat it as a momentum/re-rating trade, not a fundamental anchor. Risk/reward is acceptable only if the stock holds above the post-earnings breakout level and continues to print backlog conversion updates.
• Consider a pairs trade: long QBTS / short RGTI or IONQ over the next 1-3 months. Thesis: QBTS has the cleanest near-term commercialization catalyst set and the strongest liquidity runway; downside is that any sector-wide derating will hit all names, so size modestly.
• For higher-conviction expression, buy QBTS call spreads 2-4 months out rather than outright shares. This captures upside from another backlog/pipeline surprise while limiting damage if revenue timing pushes the story into 2026 without fresh evidence.
• Fade the move if management commentary shifts from bookings to timing language. If the next update does not show conversion into recognized revenue or new enterprise QCaaS wins within 1-2 quarters, reduce exposure aggressively because the multiple is too rich to carry execution drift.
• Watch for secondary benefits in quantum supply chain and adjacent software vendors only after QBTS demonstrates repeatable commercial deployments; until then, avoid chasing the ecosystem trade because the revenue quality is still too early-stage.